Abstract:Background: The diagnosis of familial hypercholesterolemia (FH) in children is primarily based on main criteria including low-density lipoprotein cholesterol (LDL-C) levels, increased in the proband and relatives, and its inheritance. Two other relevant parameters are symptoms, rarely occurring in children, as rare are the FH homozygous patients, and the mutation detection of related genes. The latter allows the final diagnosis, although it is not commonly available. Moreover, the application of diagnostic scores, useful in adults, is poorly applied in children. The aim of this study was to compare the reliability of criteria here applied with different scores, apart from genetic analysis, for FH diagnosis. The latter was then confirmed by genetic analysis. Methods: n. 180 hypercholesterolemic children (age 10.2 ± 4.6 years) showing LDL-C levels ≥95th percentile (age- and sex-related), the dominant inheritance pattern of hypercholesterolemia (including LDL-C ≥95th percentile in one parent), were considered potentially affected by FH and included in the study. The molecular analysis of the LDLR, APOB and PCSK9 genes was applied to verify the diagnostic accuracy. Biochemical and family history data were also retrospectively categorized according to European Atherosclerosis Society (EAS), Simon Broome Register (SBR), Pediatric group of the Italian LIPIGEN (LIPIGEN-FH-PED) and Dutch Lipid Clinic Network (DLCN) criteria. Detailed kindred biochemical and clinical assessments were extended to three generations. The lipid profile was detected by standard laboratory kits, and gene analysis was performed by traditional sequencing or Next-Generation Sequencing (NGS). Results: Among 180 hypercholesterolemic subjects, FH suspected based on the above criteria, 164/180 had the diagnosis confirmed, showing causative mutations. The mutation detection rate (MDR) was 91.1%. The scoring criteria proposed by the EAS, SBR and LIPIGEN-FH-PED (resulting in high probable, possible-defined and probable-defined, respectively) showed high sensitivity (~90%), low specificity (~6%) and high MDR (~91%). It is noteworthy that their application, as a discriminant for the execution of the molecular investigation, would lead to a loss of 9.1%, 9.8% and 9.1%, respectively, of FH-affected patients, as confirmed by the genetic analysis. DLCN criteria, for which LDL-C cut-offs are not specific for childhood, would lead to a loss of 53% of patients with mutations. Conclusions: In the pediatric population, the combination of LDL-C ≥95th percentile in the proband and the dominant inheritance pattern of hypercholesterolemia, with LDL-C ≥95th percentile in one parent, is a simple, useful and effective diagnostic criterion, showing high MDR. This pattern is crucial for early FH diagnosis. EAS, SBR and LIPIGEN-FH-PED criteria can underestimate the real number of patients with gene mutations and cannot be considered strictly discriminant for the execution of molecular analysis.

Next-generation Sequencing Verified by Multiplex Ligation-Dependent Probe Amplification to Detect a New Copy Number Variations in a Child with Heterozygous Familial Hypercholesterolemia

Identification of a Novel Mutation at the Point of Low Density Lipoprotein Receptor Gene from a Subject with Familial Hypercholesterolemia

Gene Sequencing Research of Three Familial Hypercholesterolemia Families

GW24-e3589 A novel mutation 1587_1588 del2 of the low-density lipoprotein receptor gene associated with familial hypercholesterolemia in a Chinese family

Analysis of low-density lipoprotein receptor gene mutations in a family with familial hypercholesterolemia

Research Progress in Heritable Dyslipidemia

Familial Hypercholesterolemia: Current Limitations and Future Breakthroughs

A Rapid and Scalable Multiplex PCR-Based Next-Generation Amplicon Sequencing Method for Familial Hypercholesterolemia Genetic Screening

Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia.

Identification of One Novel Mutation of the Low Density Lipoprotein Receptor Gene in Chinese Patients with Familial Hypercholesterolemia

Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia

Low-density Lipoprotein Receptor Genotypes Modify the Sera Metabolome of Patients with Homozygous Familial Hypercholesterolemia

Novel LDLR variants affecting low density lipoprotein metabolism identified in familial hypercholesterolemia

Genetic Basis of Index Patients with Familial Hypercholesterolemia in Chinese Population: Mutation Spectrum and Genotype-Phenotype Correlation

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia

Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia

LDLR c.89_92dup: a novel frameshift variation in familial hypercholesterolemia

Functional Analysis of 3 ′ UTR Variants at the LDLR and PCSK9 Genes in Patients with Familial Hypercholesterolemia

Simplified Criteria for Identification of Familial Hypercholesterolemia in Children: Application in Real Life

Cutoff Point Separating Affected and Unaffected Familial Hypercholesterolemic Patients Validated by LDL-receptor Gene Mutants.

Genetic analysis and management of a familial hypercholesterolemia pedigree with polygenic variants: Case report